Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation.
Didem Can TrabulusChester V OddisPublished in: Current rheumatology reports (2022)
Studies showing reduction in mortality rates after the use of glucocorticoids, better outcomes in patients treated with glucocorticoids compared to those who did not, and reduction of inflammation in muscle biopsies provide low level evidence to support use of glucocorticoids in myositis. Early initiation of therapy is associated with better functional outcomes. Use of intravenous methylprednisolone in patients with severe disease may lead to quicker recovery and reduction in long-term glucocorticoid exposure. Steroid-related myopathy and osteoporosis are glucocorticoid side effects that are particularly relevant in myositis. The optimal dose and duration of glucocorticoid therapy in myositis currently remain elusive, and this review emphasizes the need for better quality studies in this area.
Keyphrases
- interstitial lung disease
- myasthenia gravis
- high dose
- case control
- rheumatoid arthritis
- oxidative stress
- skeletal muscle
- postmenopausal women
- cardiovascular events
- late onset
- type diabetes
- bone mineral density
- stem cells
- low dose
- idiopathic pulmonary fibrosis
- cardiovascular disease
- metabolic syndrome
- adipose tissue
- coronary artery disease
- ultrasound guided
- body composition
- risk factors
- drug induced
- weight loss
- replacement therapy
- smoking cessation